This protocol is judged by an institutional evaluation board, an unbiased team that assessments any clinical trials involving human beings. If a study will involve a Agenda I drug, once the board approves the protocol as moral, the researchers should submit an application for an investigational new drug (IND) number through the FDA.Some researcher